FDA Releases Guidance on Clinical Holds Following Investigator Misconduct

Summary

The Food and Drug Administration (FDA) has released a guidance document outlining its procedures for imposing clinical holds on clinical trials following allegations of misconduct by investigators. The guidance aims to protect human subjects from investigator misconduct and inform interested parties about the circumstances under which a clinical hold may be imposed.